ScoreWhy is Wuhan Hiteck Biological Pharma Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of -2.50% and Operating profit at -206.91% over the last 5 years
3
The company has declared Negative results for the last 4 consecutive quarters
- NET PROFIT(9M) At CNY -112.99 MM has Grown at -104.17%
- NET SALES(HY) At CNY 278.6 MM has Grown at -21.45%
- ROCE(HY) Lowest at -10.65%
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -0.52%, its profits have fallen by -122%
5
Below par performance in long term as well as near term
- Along with generating -0.52% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Wuhan Hiteck Biological Pharma Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Wuhan Hiteck Biological Pharma Co., Ltd.
-3.31%
0.19
72.56%
China Shanghai Composite
21.43%
1.55
13.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-2.50%
EBIT Growth (5y)
-206.91%
EBIT to Interest (avg)
-56.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.25
Tax Ratio
4.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.21%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.42
EV to EBIT
-14.62
EV to EBITDA
-25.13
EV to Capital Employed
1.51
EV to Sales
4.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-10.34%
ROE (Latest)
-6.83%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
NET PROFIT(HY)
Higher at CNY 7.99 MM
NET SALES(Q)
Highest at CNY 159.05 MM
-18What is not working for the Company
NET PROFIT(9M)
At CNY -112.99 MM has Grown at -104.17%
NET SALES(HY)
At CNY 278.6 MM has Grown at -21.45%
ROCE(HY)
Lowest at -10.65%
DEBT-EQUITY RATIO
(HY)
Highest at -17.21 %
CASH AND EQV(HY)
Lowest at CNY 1,244.71 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 1.68 times
Here's what is working for Wuhan Hiteck Biological Pharma Co., Ltd.
Net Profit
At CNY 7.99 MM has Grown at 120.06%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Net Profit
Higher at CNY 7.99 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CNY MM)
Net Sales
Highest at CNY 159.05 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Net Sales
At CNY 159.05 MM has Grown at 17.5%
over average net sales of the previous four periods of CNY 135.36 MMMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Here's what is not working for Wuhan Hiteck Biological Pharma Co., Ltd.
Debt-Equity Ratio
Highest at -17.21 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Cash and Eqv
Lowest at CNY 1,244.71 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 1.68 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
